Lands' End's 15min chart sees KDJ Golden Cross and Bullish Marubozu.

Lands'End's 15-minute chart exhibited a KDJ Golden Cross and a Bullish Marubozu on October 21, 2025, at 15:00. This indicates a shift in momentum towards the upside, suggesting potential further increases in the stock price. As buyers continue to dominate the market, bullish momentum is likely to persist.

Spero Therapeutics (SPRO) stock surged on October 21, 2025, after the company announced strong Phase 3 results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTIs). The stock closed at $2.29, up 3.62% Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The pivotal Phase 3 PIVOT-PO trial demonstrated that tebipenem HBr was non-inferior to intravenous imipenem-cilastatin in treating cUTIs, including pyelonephritis. The overall success rate reached 58.5% for tebipenem HBr compared to 60.2% for the IV comparator. The trial's early termination for efficacy highlighted its strong clinical performance Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The positive clinical outcome strengthened SPRO's position as a key player in the anti-infectives market. The company confirmed its plans to advance toward FDA submission by Q4 2025, alongside GSK plc. Tebipenem HBr's success positions SPRO as a frontrunner in developing the first oral carbapenem in the United States Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The market responded positively to the announcement, boosting SPRO stock momentum. Tebipenem HBr's success maintains consistent clinical and microbiological success rates in patients with antimicrobial-resistant infections, suggesting broad applicability. SPRO's strategic focus on developing treatments that reduce dependence on intravenous antibiotics is evident in this breakthrough Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

SPRO has long pursued innovative solutions for bacterial infections with limited treatment options. The successful Phase 3 outcome adds to its record of research excellence and aligns with public health efforts to combat antimicrobial resistance. The company's work supports safer, more convenient alternatives for patients worldwide Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The development of tebipenem HBr also received funding from BARDA, highlighting government support for innovative new antibiotics. This partnership underscores SPRO's role in addressing urgent challenges related to infectious diseases. With an oral carbapenem candidate nearing approval, SPRO now stands at a transformative point in its growth Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

As regulatory preparations progress, SPRO aims to strengthen its leadership in the anti-infectives market through strategic collaborations. The company expects tebipenem HBr to enhance patient outcomes and reduce healthcare burdens caused by cUTIs. SPRO continues to gain momentum, driven by breakthrough data and expanding market potential Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].